{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-001518","form_type":"8-K","ticker":"VCEL","cik":"0000887359","company_name":"Vericel Corp","filed_at":"2024-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.156839+00:00","generated_at":"2026-06-07T01:46:36.452634+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vericel reports preliminary FY2023 revenue ~$197.5M (+20% YoY); Q4 revenue $65M (+23%)","bullets":["FY2023 preliminary total revenue ~$197.5M (+20% YoY); MACI revenue ~$164.8M (+25%); Burn Care revenue ~$32.7M.","Q4 2023 revenue ~$65M (+23% YoY); MACI $56.7M (+22%); Burn Care $8.3M (+31%); gross margin >70%.","Record-high Q4 MACI implants, implanting surgeons, biopsies, and biopsies since launch; highest Epicel biopsies since 2021.","Cash, restricted cash & investments ~$152M, no debt; adjusted EBITDA margin ~30% in Q4, mid-teens for full year.","NexoBrid U.S. launch underway with >50 burn centers submitted to P&T committees; arthroscopic MACI launch expected later in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-001518","json":"https://secwatch.observer/filing/0001140361-24-001518.json","markdown":"https://secwatch.observer/filing/0001140361-24-001518.md","text":"https://secwatch.observer/filing/0001140361-24-001518.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/887359/000114036124001518/0001140361-24-001518-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/887359/000114036124001518/ef20018464_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T01:46:36.452634+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3b0a49bcc4dbc779504709c58b2bd1b976e05329","claim":"Vericel Corp reported the fourth quarter and year ended December 31, 2023 results: revenue Total net revenue expected to be approximately $197.5 million.","evidence_excerpt":"Vericel Announces Preliminary Full-Year and Fourth Quarter 2023 Financial Results Full-Year Total Revenue Expected to be Approximately $197.5 Million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/887359/000114036124001518/0001140361-24-001518-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2023"},{"label":"Revenue","value":"Total net revenue expected to be approximately $197.5 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}